Industry Reports

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

Connected equipment ecosystems revolutionize pharmaceutical operations by integrating AI-driven analytics, digital twins, and seamless middleware to enhance visibility, collaboration, and decision-making across the value chain.

Optimize late-stage pharmaceutical assets through strategic investment planning, risk management, and indication prioritization. Maximize R&D return on investment during the highest-stakes phase of drug development.

Cardiovascular diseases, gastrointestinal conditions and cancer are top medical conditions expected to drive medical plan costs   Aon plc, a leading global professional services firm, today released the India findings from its 2026 Global Medical Trend Rates Report. The report...

It should be highlighted that during the next ten years, it is expected that the global biopharmaceutical CMO and CRO markets would expand significantly. The market is anticipated to grow at a compound annual growth rate (CAGR) of over...

Eli Lilly, the US pharma giant, has become the first drugmaker to hit $1tn valuation on November 22, 2025, hence entering the exclusive club, which is so far dominated by technology giants, highlighting its rise as a weight-loss powerhouse. The...

European venture capital firm Sofinnova Partners said on November 17 that it raised 650 million euros, equivalent to $750 million, for a new fund that is going to support the present and upcoming life sciences companies. It is well to be...